PLOD1 and type 2 diabetes mellitus: In T2DM, the testosterone-stimulating effects of both LH/hCG-R-agonists were reduced, and in MF-treated diabetic rats, they became more pronounced in comparison with diabetic rats receiving only LH/hCG-R-agonists or only MF (Table 2).